A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE1

Enrollment: 160

Sponsor: Genentech, Inc.

Summary

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Eligibility Criteria

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy of at least 12 weeks. * Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria. * Measurable disease. Exclusion Criteria: * Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to ﬁrst dose of study treatment. * Autologous stem cell transplant (SCT) with insufficient time prior to ﬁrst dose of study treatment. * Prior allogeneic SCT. * Prior solid organ transplantation.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07558915). StuddyBuddy aggregates publicly available trial information.